tradingview.comAUG 201 min read$CLOV

Clover publishes Q2 2026 supplemental Q&A highlighting Clover Assistant impact and strategy

Clover Health (CLOV) released a Q2 2026 supplemental Q&A, highlighting Clover Assistant's impact on insurance profit and member health. CA-linked members showed higher profit and better health outcomes. The company is investing in growth, expecting leverage as membership increases. Counterpart Health's rollout aims to expand lives under management.

Original reporting

tradingview.com

Published Aug 20, 2026, 8:13 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 20, 2026, 8:57 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Clover publishes Q2 2026 supplemental Q&A highlighting Clover Assistant impact and strategy — source image — Source · tradingview.com

Decision brief

The 30-second read

$CLOVBullishMed

Why it matters

The disclosed metrics provide fresh insight into the financial impact of Clover Assistant, a key growth driver.

Market read

New product performance data could affect CLOV valuation and peer comparisons.

What to watch

Implementation costs and member adoption rates are not disclosed.

Relevance 7/10Novelty 7/10Timing: filed Aug 20 2026

Background

Clover Health filed an 8‑K supplemental Q&A to elaborate on its Q2 2026 results and future strategy.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CLOVBullishHigh confidence

Context

Clover Health disclosed supplemental Q&A with new metrics on Clover Assistant impact, including $155 higher insurance gross profit PMPM and 18% better MCR.

Expected impact

Potential upside as market digests improved economics.

Evidence & confidence

New quantitative data on product performance and cost savings are material for valuation.

Market effects

Sector

Highlights health‑tech efficiency gains, may influence peer valuations.

Regional

U.S. health‑tech sector could see modest re‑rating.

Global

Limited to U.S. listed health‑tech investors.

Counterpoint

What could challenge this read

Skeptics may question scalability of Clover Assistant benefits.

Key entities

company
Clover Health Investments, Corp.
U.S. listed health‑tech firm (ticker CLOV).
product
Clover Assistant
AI‑driven health management platform.

Read at source ← All news

SEP 15

$ASTHMed

Astrana Health, Clover Health, Alignment Healthcare, and Novavax Stocks Trade Down, What You Need To Know

Several healthcare stocks fell after bipartisan lawmakers introduced the Protecting Approved Care Act, which aims to reform Medicare Advantage plans. The bill could increase medical loss ratios and administrative burdens for insurers. Astrana Health (ASTH) fell 2.7%, Clover Health (CLOV) 4.8%, Alignment Healthcare (ALHC) 12.6%, and Novavax (NVAX) 3.6%.

financialcontent.com2 min

SEP 11

$CLOVHigh

Clover Health (CLOV) Gets New ‘Buy’ Call, Higher PT, Climbs 8.5%

Clover Health (CLOV) shares rose 8.53% to $4.71 after Deutsche Bank initiated coverage with a 'buy' rating and $6 price target, citing growth potential in Medicare Advantage and its technology platform. The company reported Q2 net income of $28M, up from a $10.6M loss YoY, with revenues increasing 55.6% to $743.2M. Medicare Advantage membership grew 48% to 157,309. Clover raised its net income and revenue guidance for the year. Hedge fund holdings in CLOV increased fourfold to $79.06M.

yahoo.com2 min

SEP 10

$CLOVMed

Clover Health (CLOV) Shares Skyrocket, What You Need To Know

Clover Health (CLOV) shares rose 8.5% after Deutsche Bank initiated coverage with a Buy rating and $6.00 price target, citing growth in Medicare Advantage, its Clover Assistant platform, and its risk model. The stock has seen high volatility, with a 24.2% drop last year due to disappointing earnings and lowered guidance. CLOV is up 96.9% YTD but trades 12.3% below its 52-week high.

financialcontent.com2 min

SEP 10

$PGNYHighAI 8/10

Spotting Winners: Progyny (NASDAQ:PGNY) And Health Insurance Providers Stocks In Q2

Progyny (PGNY) and other health insurers reported Q2 earnings, with revenues beating estimates by 2.8% but guidance below expectations. PGNY's revenue grew 5.3% YoY, missing EBITDA guidance. CVS Health (CVS) reported 7.3% YoY revenue growth, beating estimates. Molina Healthcare (MOH) saw a 4.8% YoY revenue decline. Alignment Healthcare (ALHC) grew 31.6% YoY, while Clover Health (CLOV) saw 55.6% YoY growth. Stocks have declined since earnings, except CLOV, which rose 4.3%.

tradingview.com3 min

SEP 3

$CLOVHighAI 8/10

Clover Health (CLOV) Turns Profitable As Medicare Membership Explodes

Clover Health (CLOV) reported Q2 2026 net income of $28M, reversing a $10.6M loss from the prior year. Medicare Advantage membership grew 48% YoY to 157,309. Revenue rose 55.6% to $743.2M, and adjusted EBITDA more than doubled. The company raised its full-year guidance, including adjusted EBITDA to $70M-$85M and GAAP net income to $20M-$35M. Cash and investments increased 13.8% YoY to $443.0M.

insidermonkey.com3 min

AUG 13

$CLOVHighAI 9/10

Clover Health (CLOV) Q2 2026 Earnings Call Transcript

Clover Health (CLOV) reported Q2 2026 results on an earnings call. It said Medicare Advantage membership rose to 157,309 (+48% YoY), revenue was $743.2M (+55.6%), GAAP net income was $28M, and non-GAAP adjusted EBITDA was $40.9M. FY2026 guidance was raised to $2.92B-$3.0B revenue and $70M-$85M adjusted EBITDA.

fool.com6 min